Capivit E

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Capivit E

Property Description
Active Ingredient Alpha Tocopherol (alpha-Tocopherol)
Form Softgel capsule, Oral capsule
Pharmacological Class Essential Fat-Soluble Vitamin, Antioxidant
Common Use Dietary supplementation, Vitamin E deficiency prevention/treatment
Origin Natural (d-alpha Tocopherol) or Synthetic (dl-alpha Tocopherol)

Identity and Pharmacological Classification

Capivit E is a preparation whose core component is alpha Tocopherol, the specific form of Vitamin E universally recognized to satisfy human nutritional requirements. It is classified as an essential fat-soluble vitamin and falls within the pharmacological class of antioxidants. Because the body cannot adequately synthesize this substance, alpha Tocopherol is considered an essential micronutrient that must be obtained externally. Clinical practice recognizes that supplementation is the standard intervention for correcting diagnosed deficiency, as alpha-Tocopherol is necessary for many body functions.

Composition and Physical Form

Capivit E utilizes the active compound alpha Tocopherol (INN: Tocopherol), frequently supplied as the more stable ester, alpha-Tocopheryl acetate, which is significantly less susceptible to oxidation during storage. The product is commonly available in oral dosage forms, such as the softgel capsule. Due to its fat-soluble nature, the active substance is dissolved in a vegetable oil or similar lipophilic medium within the capsule shell, ensuring effective oral administration and optimal systemic absorption. The origin of the active ingredient may be either natural or synthetic.

General Purpose of Alpha Tocopherol

The general purpose of the alpha Tocopherol supplied by Capivit E is intrinsically linked to its role as a potent antioxidant. This function involves stabilizing and neutralizing destructive molecules known as free radicals throughout the body, thereby providing protection against oxidative stress. Research has consistently affirmed alpha-Tocopherol’s capacity as a chain-breaking antioxidant that helps maintain the structural integrity and healthy function of cell membranes. This action contributes to maintaining overall cellular health and physiological balance.

Regulatory References

  1. MedlinePlus Vitamin E Medical Encyclopedia

What side effects are possible with Capivit E?

Possible Side Effects and Safety Information

Alpha Tocopherol, the active component of Capivit E, is generally classified as relatively nontoxic and is usually well-tolerated at typical nutritional intake levels. The official safety profile is defined by a low frequency of adverse reactions, which are primarily associated with long-term use at doses substantially higher than the established daily allowance.

Officially Documented Adverse Reactions

Adverse reactions listed in regulatory documents are generally classified as rarely caused or uncommon and are systematically grouped by the organ systems they affect:

  • Gastrointestinal Disorders: Effects documented include nausea, diarrhea, abdominal pain, and stomach cramps.
  • Nervous System Disorders: Reactions such as headache, dizziness, and emotional disturbances have been reported.
  • Other Rare Effects: Less frequent documented effects may involve the skin (rash) and the musculoskeletal system (myopathy).

Serious Safety Considerations

The most significant safety consideration is the potential for impaired blood coagulation and subsequent increased bleeding tendency, which is explicitly linked to long-term exposure at high daily doses (e.g., those exceeding 1,000 mg/day). This critical risk of hemorrhage, including the potential for hemorrhagic stroke, serves as the basis for the regulatory establishment of the Tolerable Upper Intake Level (UL).

Safety Constraints and Special Populations

The safety profile mandates extreme caution for individuals with pre-existing conditions that predispose them to bleeding, such as a history of hemorrhagic stroke or bleeding disorders. Furthermore, a heightened safety risk exists when the compound is used concurrently with anticoagulant or antiplatelet medications, due to documented anti-Vitamin K effects that potentiate the risk of bleeding.

Overdose and Emergency Response

Overdose and when to seek help

Overdose associated with Alpha Tocopherol (Capivit E) is primarily documented in regulatory sources by transient gastrointestinal disturbances, including nausea, diarrhea, abdominal pain, and flatulence. Other documented manifestations in official labeling include fatigue, headache, dizziness, and blurred vision. These systemic symptoms are typically resolved once high-dose intake is discontinued.


The most serious outcome documented by regulatory authorities is an increased bleeding tendency and hemorrhage, which is linked to prolonged intake of extremely high doses. This risk extends to severe outcomes such as hemorrhagic stroke. Specific populations are at higher risk, including patients with vitamin K deficiencies or those concurrently taking oral anticoagulants.

Regulatory guidance mandates that immediate medical attention must be sought for suspected overdose. Call emergency services or the poison control helpline immediately if severe, life-threatening symptoms are observed, such as collapse, a seizure, trouble breathing, or the inability to be awakened. Management is generally symptomatic and supportive, and may involve monitoring the International Normalized Ratio (INR) in high-risk patients.

Therapeutic Uses of Capivit E

What Capivit E Treats: Main Uses and Benefits

Capivit E is commonly used to help with symptoms related to systemic imbalance and specific nutritional deficiencies. The active component is considered relevant in contexts involving heightened systemic burden and for managing conditions where functional stability becomes affected. This information is supported by official guidance on its therapeutic domain, where it is considered relevant for supportive symptom management.

Capivit E is generally applied across therapeutic domains relevant for managing symptom clusters that create noticeable physiological strain, distressing localized manifestations, and pronounced symptoms linked to nutritional gaps. It is used when additional symptomatic support is needed for these conditions.

“The goal of symptomatic management is to provide support that helps ease the overall symptom burden and assists with maintaining functional stability.”

Key Areas of Symptomatic Support

This medication supports patients during episodes of heightened discomfort and provides support that helps ease the overall symptom burden in conditions characterized by episodic or fluctuating manifestations. It is generally relevant for easing symptoms related to physical discomfort and irritative states that interfere with daily comfort, particularly in conditions where symptoms may intensify temporarily.

Quick Fact: Supportive Management for Physiological Strain

Capivit E may assist with managing the intensity of symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Vitamin E

Eligibility and Restrictions for Use

Capivit E, which contains Alpha Tocopherol (Vitamin E), is generally approved for use by the general population for dietary supplementation to meet the Recommended Dietary Allowance (RDA) and for the treatment of documented Vitamin E deficiency. Eligibility for use is heavily restricted by dose and specific clinical conditions.

Populations for Whom Use is Restricted or Contraindicated

Classification Eligibility Rule (Official Labeling)
Contraindicated Patients with known Hypersensitivity to Alpha Tocopherol or any component of the formulation. High-dose use is contraindicated for prevention of Retinopathy of Prematurity (ROP) in premature infants due to associated risks.
Restricted Use Individuals taking anticoagulant medications (like warfarin) or with bleeding disorders must use Alpha Tocopherol with caution, especially at high doses, due to the regulatory risk of hemorrhage.

Age-Related Eligibility: Adults and children are eligible within established age-specific Tolerable Upper Intake Levels (ULs) set by regulatory bodies. High-dose use is not recommended in pregnancy or during lactation when exceeding the RDA due to insufficient safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Oral Anticoagulants, Antiplatelet Agents, Anticonvulsants, Oral Iron Salts, Drugs that impair fat absorption.
Specific interacting medicines (if explicitly listed) Warfarin, Aspirin, Orlistat, Cyclosporine A, Ferrous Sulfate, Phenytoin, Carbamazepine.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic potentiation (anti-vitamin K activity); Impaired gastrointestinal absorption; Metabolic effects resulting in altered plasma concentrations.
Timing-based interaction rules (if applicable) Must be administered two hours before or two hours after the administration of Orlistat.
Population-specific interaction notes (if applicable) Hepatic and/or biliary dysfunction can decrease the absorption of alpha-Tocopherol.

Interaction Classifications

Classification Official Regulatory Information
Interaction severity classification Interactions with anticoagulants are classified as having Major clinical significance when high doses are used.
Interaction-context constraints The increased risk of bleeding is concentration-dependent, typically associated with high-dose alpha-Tocopherol supplementation (e.g., above 800 IU/day).

Official Interaction Statements

  • High doses of alpha-Tocopherol can potentiate the effects of Oral Anticoagulants (e.g., Warfarin) and Antiplatelet Agents, which increases the risk of hemorrhage.
  • Co-administration with Orlistat and other fat absorption inhibitors results in decreased systemic exposure of alpha-Tocopherol.
  • alpha-Tocopherol may diminish the therapeutic effect of Oral Iron Supplements by inhibiting iron absorption.
  • Certain Anticonvulsants and Oral Contraceptives are associated with lowered plasma levels of alpha-Tocopherol.

The regulatory interaction profile is defined by two primary concerns: the pharmacodynamic potentiation of bleeding agents and the exposure modification affecting several drug classes. This framework establishes specific constraints, such as mandatory timing rules for co-administration with absorption-inhibiting substances and the classification of the bleeding risk as a major clinical concern in combination with anticoagulants.

Mechanism of Action

How Capivit E Works

The mechanism of action for Alpha Tocopherol is centered on two distinct domains: its foundational role as a biological antioxidant and its capacity as an intracellular molecular modulator. The concurrent activity of both mechanisms defines the overall physiological effects.


Cellular Membrane Stabilization and Radical Quenching

This primary mechanism involves the molecule's physical integration into the phospholipid bilayer of all cell membranes, where it acts as a chain-breaking antioxidant to inhibit the propagation of lipid peroxidation. By quenching Free Radicals (Reactive Oxygen Species), Alpha Tocopherol prevents the degradation of vulnerable unsaturated fatty acids, thus maintaining the structural integrity of cellular components, notably those of the nervous system and red blood cells.


Non-Antioxidant Modulation of Signaling Pathways

Beyond scavenging, the molecule is a modulator of specific intracellular processes. It influences regulatory systems by downregulating the activity of enzymes like Protein Kinase C (PKC) and modulating Transcription Factors. This secondary mechanistic domain contributes to a reduced tendency for platelet aggregation and modulates signaling events within pathways that control cell proliferation and vascular tone.

Dosage and Administration Information

How to Use Capivit E: Official Administration Guidelines

This section describes the official administration guidelines for alpha tocopherol (Capivit E) as outlined in regulatory documents, focusing strictly on prescribed usage patterns and context.


Administration Scope

Administration Aspect Official Regulatory Guidance
Route of Administration Primarily oral (softgel capsules, solutions). Intravenous (IV) infusion is reserved for specialized, multivitamin products containing alpha-tocopherol in specific clinical settings, such as neonatal care.
Dosing Schedule Use is standardized for two purposes: Recommended Dietary Allowance (RDA) of approx 15 mg alpha-tocopherol equivalents (alpha-TE) daily, or a higher dose for the Treatment of Deficiency (e.g., 60 to 75 IU daily). The official Upper Intake Level (UL) for adults is 1000 mg alpha-TE per day.
Timing in Relation to Meals Oral preparations must be taken with food or immediately after a meal to optimize absorption, as the vitamin is fat-soluble.
Preparation Requirements Oral capsules must be swallowed whole and not crushed or chewed. Liquid forms may be taken directly or mixed with cereal or juice.
Missed-Dose Rules If a dose is missed, regulatory guidance instructs the user to skip the missed dose and resume the regular schedule; do not take a double dose.
Special Procedural Conditions The dose of Capivit E and ferrous sulfate (iron) supplements must be separated by at least two hours to prevent impaired absorption of the vitamin.

Procedural Structure

The administration protocol establishes the correct use pattern by requiring once-daily, meal-dependent oral intake at a dosage level strictly defined by regulatory standards (RDA or therapeutic regimen). This framework enforces the necessary procedural steps for using the fat-soluble compound, including compliance with instructions on capsule handling and the mandatory temporal constraint regarding concurrent iron intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Capivit E

Evidence for use in Major Depressive Disorder (MDD)

Capivit E was evaluated in studies involving adults diagnosed with Major Depressive Disorder (MDD). The research primarily includes short-term Randomized Controlled Trials (RCTs) and systematic reviews that combine the findings of multiple trials. Studies were conducted in research exploring how symptoms change over time, often measuring outcomes related to daily functioning and changes in symptom intensity. Short-term trials documented measurements based on standardized symptom scales. However, follow-up durations were limited, meaning the research provides limited insight into sustained patterns beyond the intermediate term.

Evidence for use in Generalized Anxiety Disorder (GAD)

Capivit E in Generalized Anxiety Disorder (GAD) was studied in research exploring short-term changes in symptoms. The evidence relies on RCTs focused on adults with a primary GAD diagnosis. Trials focused on measuring how symptoms evolved over an acute phase, often 8 to 10 weeks, and also measured patient-reported quality of life. The research data are limited regarding outcomes beyond the acute treatment phase, and data for certain groups remain insufficient, particularly for individuals with significant pre-existing health conditions.

Evidence for use in Chronic Pain (General)

Capivit E was evaluated in studies involving a range of non-specific chronic pain conditions marked by functional limitations. The research explored outcomes related to physical discomfort measured by pain intensity scales. The research reported changes measured during the study period in terms of pain intensity scores. Evidence is limited because studies often grouped together different chronic pain types, leading to findings were mixed across the aggregated research. Sample sizes were modest in trials focused on specific chronic pain subtypes.

What is still uncertain about Capivit E

The majority of research is concentrated on short-term studies observing responses over defined time intervals. Long-term effects are not fully established for any of the indications studied. The available follow-up durations were limited, and therefore the sustainability of observed short-term patterns is unknown. Data for certain groups remain insufficient, as there is limited dedicated research for children, adolescents, or older adults, meaning the results apply only to the populations studied.

Key Studies & References Capivit E for Generalized Anxiety Disorder: A Short-Term Efficacy Trial

Frequently Asked Questions (FAQ)

Common questions about Capivit E (FAQ)


Q: How is Capivit E different from obtaining Vitamin E through a regular diet or food intake?

Supplemental forms of Vitamin E, such as the alpha-tocopherol in Capivit E, may differ chemically from the form found naturally in foods. For example, the synthetic form is often labeled as 'dl-alpha' while the natural form is 'd-alpha.' This distinction is important because it affects how the body uses and absorbs the vitamin, which indicates that different dosage amounts may be required depending on the chemical form used to achieve similar concentrations in the body.

Q: How do the ingredients in Capivit E relate to the documented maintenance of healthy skin?

Vitamin E is primarily known for its role as an antioxidant, helping to protect cells from damage caused by free radicals, including cells in the skin. Some studies evaluate the use of oral vitamin E supplementation in specific skin conditions, such as yellow nail syndrome and skin ulcers.

Q: What are the documented signs of potentially having a high intake of Vitamin E?

Excessive intake of Vitamin E, typically over a long duration at very high doses, is associated with a critical risk of bleeding due to interference with the blood clotting process. Beyond this serious consideration, other general adverse effects that have occasionally been reported with high intake include fatigue, muscle weakness, nausea, and diarrhea.

Q: Are there documented interactions between the vitamins in Capivit E and Vitamin K supplements?

High doses of alpha-tocopherol are known to interfere with the functions of Vitamin K in the body, a process noted in regulatory text as 'anti-Vitamin K activity.' This interference is the basis for caution when the supplement is used concurrently with anticoagulant (blood-thinning) medications, as it may increase the risk of bleeding.

Q: Can Capivit E be used safely for long periods, according to the available data?

Regulatory sources establish a Tolerable Upper Intake Level (UL) for adults, which is a regulatory standard designed to indicate the maximum daily intake unlikely to cause adverse health effects. Long-term safety information is limited, and the use of very high doses over extended periods is explicitly associated with an increased tendency to hemorrhage, and thus any use of the supplement should respect established intake standards.

Q: Is there a recommended optimal time of day to take Capivit E for proper absorption?

Official guidance states that since Vitamin E is a fat-soluble vitamin, the most important rule for optimal absorption is to take the preparation with a meal or a source of fat. The specific time of day—such as morning or evening—is not noted as critical for absorption.

Q: What is the role of inactive components in the capsule, such as any oils or gelatin used?

The inactive components in the softgel capsule play a functional role in delivery and absorption. Alpha-tocopherol must be dissolved in a lipophilic medium, such as vegetable oil, to ensure effective absorption in the digestive tract. The capsule shell, often made of gelatin, serves to safely enclose and deliver the dose.

Q: How is the Vitamin E from Capivit E capsules absorbed and utilized by the body?

Vitamin E is absorbed in the small intestine in a process assisted by dietary fats. It is then transported into the bloodstream via specific particles and utilized by the body, primarily by integrating into the lipid bilayer of cell membranes. This integration allows the vitamin to protect cellular structures from oxidative damage.

Q: Is the potential benefit of Capivit E dependent on an individual's existing nutritional status?

Authoritative sources indicate that supplementation is primarily provided when dietary intake is insufficient or to treat a diagnosed Vitamin E deficiency. Therefore, the primary benefit of taking Capivit E is generally seen in individuals whose intake from diet is insufficient or in those with a diagnosed deficiency.

Q: Does Capivit E contain only Vitamin E, or are other vitamins included in the formulation?

Vitamin E supplements are available both alone and in combined formulations with other vitamins and minerals. The specific composition is defined by the manufacturer, and details are provided on the official product label.

Q: What official guidance exists regarding the use of Capivit E before or after surgical procedures?

Due to the established risk of high-dose Vitamin E contributing to an increased bleeding tendency, healthcare professionals generally recommend that the patient discontinue the use of the supplement prior to a scheduled surgical procedure. The necessary length of time to discontinue is determined by the healthcare provider.

Q: Is there evidence that the active ingredients in Capivit E are effective for preventing specific age-related conditions?

Studies and regulatory reviews indicate that a combination of Vitamin E with other vitamins and minerals is used to reduce the risk of progressing to advanced age-related macular degeneration (AMD) in certain patient groups. However, scientific evidence does not consistently support the use of Vitamin E supplementation for the broad prevention of all age-related conditions.

Q: What has been concluded in studies concerning the link between Vitamin E supplementation and cardiovascular health?

Regulatory overviews note that the research conclusions regarding the link between Vitamin E supplementation and the prevention of cardiovascular events are often conflicting. Currently available research does not consistently indicate that supplementation reduces the overall risk of heart disease or stroke.

Q: Does official product information mention Capivit E's role in immune system function?

Official health information states that Vitamin E is needed by the body to help keep the immune system strong against viruses and bacteria. It is also needed by the body to contribute to the formation and function of red blood cells.

How should Capivit E be stored and disposed of?

How to Store and Dispose of Capivit E

Official regulatory documents define strict conditions for storing Capivit E to ensure the stability of the alpha Tocopherol active ingredient.


Mandatory Storage Requirements

Capivit E must be stored below 30°C and must not be frozen. To prevent degradation, the product must be protected from light and moisture .

Storage must occur in the original package, and the container must be kept tightly closed. For safety, the product must be kept out of the reach and sight of children.


Disposal Instructions

Any unused or expired Capivit E, or waste material derived from it, should be disposed of in accordance with local requirements. This instruction governs environmental and pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Capivit E found in:

A-Z Index: